Cancer is a leading global cause of death, with complex pathogenesis and treatment challenges like poor selectivity, toxicity, and drug resistance. Nanotechnology offers transformative solutions, with plant-derived exosomes (EXOs) emerging as promising green nanomaterials for personalized cancer therapy because of their biocompatibility and minimal antigenicity, and eco-friendly production. This review discusses the potential of plant EXOs in cancer treatment, covering isolation methods, advantages over mammalian EXOs (e.g., stability, cost-effectiveness, and evasion of drug resistance mechanisms), and preclinical applications. For instance, ginger EXOs suppress colorectal cancer via cytokine modulation, grapefruit EXOs target brain tumors, and lemon EXOs induce apoptosis in triple-negative breast cancer. Plant EXOs also enhance drug delivery when loaded with chemotherapeutics, nucleic acids, or immunomodulators, improving precision and reducing off-target effects. Despite their promise, challenges remain in scalability, purity, long-term safety for non-oral routes, and clinical translation. Future research must optimize isolation techniques, clarify molecular mechanisms, and validate pharmacokinetics to advance clinical adoption. This review offers a complete examination of plant EXOs, including biogenesis, characterization, engineering strategies, anti-cancer mechanisms (e.g., apoptosis induction, immune modulation), and therapeutic applications. It also addresses hurdles like standardization and regulatory gaps while advocating interdisciplinary collaboration to bridge lab-to-clinic gaps. By harnessing plant EXOs' potential, this work highlights a path toward sustainable, targeted cancer therapies, urging further innovation to overcome existing barriers and realize their full clinical impact.
Drug Development and Industrial Pharmacy · مجلد 51 (8) · 930-942
PURPOSE: To address the challenges of frequent glipizide dosing, including its variable bioa-vailability and gastrointestinal side effects, this study developed and evaluated mucoadhesive buccal films using natural proteins (albumin, gelatin, casein) combined with HPMC E15 to achieve sustained drug delivery. METHODS: Nine formulations (F1-F9) were prepared using solvent casting technique and sys-tematically characterized. Comprehensive evaluations included: (1) drug-polymer compatibil-ity studies (FT-IR, DSC), (2) physicochemical characterization (thickness, weight uniformity, swelling index, moisture content, folding endurance, surface pH), (3) ex-vivo permeation studies through sheep buccal mucosa, and (4) stability assessments to determine film longevi-ty. RESULTS: Compatibility studies utilizing FT-IR and DSC confirmed no significant incompati-bility between glipizide and the excipients. Some of the important physicochemical character-istics recorded for different formulations were surface pH (6.6 - 6.8), folding endurance (72 - 184), moisture content (5.66 - 12.54%), thickness (0.171 - 0.236 mm), weight (0.150 - 0.238 mg), and swelling index (15.8% after 1 hour to 86.6% after 5 hours). Furthermore, neg-ligible variation was observed in these characteristics when stability studies were conducted after 3 months. The ex-vivo permeation studies demonstrated a sustained release of glipizide over 8 hours, with release percentages ranging from 80.94% to 90%. Formulation F6, which achieved an 8-hour release of 89.29%, was identified as optimal. Kinetic analysis revealed zero-order release kinetics for all formulations. CONCLUSION: The developed mucoadhesive buccal films exhibited excellent sustained-release properties, representing a significant improvement over conventional dosage forms. This in-novative delivery system shows strong potential for enhancing diabetes management through improved bioavailability and patient compliance, while minimizing gastrointestinal side effects.
mucoadhesive buccal filmsglipizidesustained drug releasenatural proteins
Journal of Biomolecular Structure and Dynamics · مجلد 41 (17) · 8307-8322
Tyrosinase enzyme plays an essential role in melanin biosynthesis and enzymatic browning of fruits and vegetables. To discover potent tyrosinase inhibitors, the present studies were undertaken. In this context, synthetic aurone derivatives 26–50 were designed, synthesized, and structurally elucidated by various spectroscopic techniques including IR, UV, 1H- & 13C-NMR and mass spectrometry. The target compounds 26–50 were screened for their anti-tyrosinase inhibitory potential, and thus kinetic mechanism was analyzed by Lineweaver-Burk plots. All target compounds exhibited good to excellent IC50 values in the range of 7.12 ± 0.32 μM to 66.82 ± 2.44 μM. These synthesized aurone derivatives were found as potent tyrosinase inhibitors relative to the standard kojic acid (IC50 = 16.69 ± 2.81 μM) and the compound 39 inhibited tyrosinase non-competitively (Ki = 11.8 μM) by forming an enzyme-inhibitor complex. The binding modes of these molecules were ascribed through molecular docking studies against tyrosinase protein (PDB ID: 2Y9X). The quantitative structure-activity relationship studies displayed a good correlation between 26–50 structures and their anti-tyrosinase activity (IC50) with a correlation coefficient (R2) of 0.9926. The computational studies were coherent with experimental results and these ligands exhibited good binding values against tyrosinase and interacted with core residues of target protein. Moreover, the drug-likeness analysis also showed that some compounds have a linear correlation with Lipinski’s rule of five, indicating good drug-likeness and bioactivity scores for pharmacological targets. Communicated by Ramaswamy H. Sarma
At present, people and patients worldwide are relying on the medicinal plant as a therapeutic agent over pharmaceuticals because the medicinal plant is considered safer, especially for chronic disorders. Several medicinal plants and their components are being researched and explored for their possible therapeutic contribution to CNS disorders. Thymoquinone (TQ) is one such molecule. Thymoquinone, one of the constituents of Plant Nigella Sativa, is effective against several neurodegenerative diseases like, Alzheimer's, Depression, Encephalomyelitis, Epilepsy, Ischemia, Parkinson's, and Traumatic. This review article presents the neuropharmacological potential of TQ's, their challenges, and delivery prospects, explicitly focusing on neurological disorders along with their chemistry, pharmacokinetics, and toxicity. Since TQ has some pharmacokinetic challenges, scientists have focused on novel formulations and delivery systems to enhance bioavailability and ultimately increase its therapeutic value. In the present work, the role of nanotechnology in neurodegenerative disease and how it improves the bioavailability and delivery of a drug to the site of action has been discussed. There are a few limitations to developing novel drug formulations, including solubility, pH, and compatibility of nanomaterials. Since here we are targeting CNS disorders, the bloodbrain barrier (BBB) becomes an additional challenge. Hence, the review summarized the novel aspects of delivery and biocompatible nanoparticles-based approaches for targeted drug delivery into CNS, enhancing TQ bioavailability and its neurotherapeutic effects.
Biotechnology and Applied Biochemistry · مجلد 70 (1) · 290-305
Abstract The processive cellulase (CelO) is an important modular enzyme of Clostridium thermocellum . To study the effect of the carbohydrate‐binding module (CBM3b) on the catalytic domain of CelO (GH5), four engineered derivatives of CelO were designed by truncation and terminal fusion of CBM3b. These are CBM at the N‐terminus, native form (CelO‐BC, 62 kDa); catalytic domain only (CelO‐C, 42 kDa); CBM at the C‐terminus (CelO‐CB, 54 kDa) and CBM attached at both termini (CelO‐BCB, 73 kDa). All constructs were cloned into pET22b (+) and expressed in Escherichia coli BL21 (DE3) star. The expression levels of CelO‐C, CelO‐CB, CelO‐BC, and CelO‐BCB were 35%, 35%, 30%, and 20%, respectively. The enzyme activities of CelO‐C, CelO‐CB, CelO‐BC, and CelO‐BCB against 1% regenerated amorphous cellulose (RAC) were 860, 758, 985, and 1208 units per μmole of the enzyme, respectively. The enzymes were partially purified from the lysate of E. coli cells by heat treatment followed by anion exchange FPLC purification. Against RAC, CelO‐C, CelO‐CB, CelO‐BC, and CelO‐BCB showed K M values of 32, 33, 45, and 43 mg⋅mL –1 and V max values of 3571, 3846, 3571, and 4545 U⋅min –1 , respectively. CBM3b at the N‐terminus of GH5 linked through a P/T‐rich linker was found to enhance the catalytic activity and thermostability of the enzyme.
Despite many ongoing efforts across the full spectrum of pharmaceutical and biotech industries, drug development is still a costly undertaking that involves a high risk of failure during clinical trials. Animal models played vital roles in understanding the mechanism of human diseases. However, the use of these models has been a subject of heated debate, particularly due to ethical matters and the inevitable pathophysiological differences between animals and humans. Current in vitro models lack the sufficient functionality and predictivity of human pharmacokinetics and toxicity, therefore, are not capable to fully replace animal models. The recent development of micro-physiological systems has shown great potential as indispensable tools for recapitulating key physiological parameters of humans and providing in vitro methods for predicting the pharmacokinetics and pharmacodynamics in humans. Integration of Absorption, Distribution, Metabolism, and Excretion (ADME) processes within one close in vitro system is a paramount development that would meet important unmet pharmaceutical industry needs. In this review paper, synthesis of the ADME-centered organ-on-a-chip technology is systemically presented from what is achieved to what needs to be done, emphasizing the requirements of in vitro models that meet industrial needs in terms of the structure and functions.